Patent Number(s), Dates Issued, Patent Holder's Name
Patent 4,649,047: Ophthalmic treatment by topical administration of cyclosporin; a method for the treatment of either phacoanaphylactic endophthalmitis or uveitis by administering at least one cyclosporin topically to the eyes. Topical application of cyclosporin provides cyclosporin to the anterior chamber, the posterior chamber and the vitreous body of the eye.
- Filed: March 19, 1985
- Inventors: Dr. Renee Kaswan
- Assignee: University of Georgia Research Foundation
- Commercial Name: Restasis®, Optimmune®
Patent 4,839,342: Method of increasing tear production by topical administration of cyclosporin; a method of treating an aqueous-deficient dry eye state in a patient suffering there from, which method includes the step of administering cyclosporin topically to the patient's eye. The cyclosporin is administered as a solution, suspension or ointment in a pharmaceutically acceptable excipient.
- Filed: September 3, 1987
- Inventors: Dr. Renee Kaswan
- Assignee: University of Georgia Research Foundation
- Commercial Name: Restasis®, Optimmune®
Patent 5,411,952: Ocular cyclosporine composition; cyclosporine compositions for topical ophthalmic use for treatment of immune disorders, to enhance or restore tear production, and to enhance or effect normal healing of the surface of the eye, containing cyclosporine dissolved in corn oil.
- Filed: February 6, 1990
- Inventors: Dr. Renee Kaswan
- Assignee: University of Georgia Research Foundation
- Commercial Name: Restasis®, Optimmune®
|
